Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 10, Issue 1, 2006, Pages 89-109

  De La Monte, Suzanne M ^a   Tong, Ming ^a   Lester Coll, Nataniel ^a   Plater Jr , Michael ^a   Wands, Jack R ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Growth factor receptors; Insulin; Insulin sensitizers; Peroxisome proliferator activated receptor; RT PCR; Streptozotocin; Therapy; Type 3 diabetes

Indexed keywords

INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SOMATOMEDIN RECEPTOR;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LEARNING; MAZE TEST; MEMORY; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; WESTERN BLOTTING;

EID: 33748755428     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2006-10113     Document Type: Article

References (31)

1. S.M. de la Monte and J.R. Wands, Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease, J Alzheimers Dis 7(1) (2005), 45-61.
2. E. Steen, B.M. Terry, E.J. Rivera, J.L. Cannon, T.R. Neely, R. Tavares, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7(1) (2005), 63-80.
3. E.J. Rivera, A. Goldin, N. Fulmer, R. Tavares, J.R. Wands and S.M. de la Monte, Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine, J Alzheimers Dis 8(3) (2005), 247-268.
4. R.D. Terry and R. Katzman, Senile dementia of the Alzheimer type, Ann Neurol 14(5) (1983), 497-506.
5. N. Lester-Coll, E.J. Rivera, S.J. Soscia, K. Doiron, J.R. Wands and S.M. de la Monte, Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease, J Alzheimers Dis 9(1) (2006), 13-33.
6. K. Plaschke and S. Hoyer, Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus, Int J Dev Neurosci 11(4) (1993), 477-483.
7. R. Duelli, H. Schrock, W. Kuschinsky and S. Hoyer, Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats, Int J Dev Neurosci 12(8) (1994), 737-743.
8. S. Hoyer, S.K. Lee, T. Loffler and R. Schliebs, Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 920 (2000), 256-258.
9. S. Hoyer and H. Lannert, Inhibition of the neuronal insulin receptor causes Alzheimer-like disturbances in oxidative/energy brain metabolism and in behavior in adult rats, Ann N Y Acad Sci 893 (1999), 301-303.
10. H. Lannert and S. Hoyer, Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats, Behav Neurosci 112(5) (1998), 1199-208.
11. S.M. de la Monte and J.R. Wands, Molecular Indices of mitochondrial dysfunction and oxidative stress occur early and increase with progression of alzheimer's disease, J Alz Dis 9 (2006), in Press.
12. R.W. Hickey, M. Akino, S. Strausbaugh and G.M. De Courten-Myers, Use of the Morris water maze and acoustic startle chamber to evaluate neurologic injury after asphyxial arrest in rats, Pediatr Res 39(1) (1996), 77-84.
13. S.M. de la Monte, T. Luong, T.R. Neely, D. Robinson and J.R. Wands, Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease, Lab Invest 80(8) (2000), 1323-1335.
14. J.E. Yeon, S. Califano, J. Xu, J.R. Wands and S.M. De La Monte, Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver, Hepatology 38(3) (2003), 703-714.
15. J. Xu, J. Eun Yeon, H. Chang, G. Tison, G. Jun Chen, J.R. Wands et al., Ethanol impairs insulin-stimulated neuronal survival in the developing brain: Role of PTEN phosphatase, J Biol Chem (2003).
16. F. Ausubel, R. Brent, R. Kingston, D. Moore, J. Seidman, J. Smnith et al., Current Protocols in Molecular Biology (2000).
17. K. Iqbal, C. Alonso Adel, S. Chen, M.O. Chohan, E. El-Akkad, C.X. Gong et al., tau pathology in Alzheimer disease and other tauopathies, Biochim Biophys Acta 1739(2-3) (2005), 198-210.
18. S. Lovestone, C.H. Reynolds, D. Latimer, D.R. Davis, B.H. Anderton, J.M. Gallo et al., Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells, Curr Biol 4(12) (1994), 1077-1086.
19. M. Schubert, D.P. Brazil, D.J. Burks, J.A. Kushner, J. Ye, C.L. Flint et al., Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation, J Neurosci 23(18) (2003), 7084-7092.
20. M. Schubert, D. Gautam, D. Surjo, K. Ueki, S. Baudler, D. Schubert et al., Role for neuronal insulin resistance in neurodegenerative diseases, Proc Natl Acad Sci USA 101(9) (2004), 3100-3105.
21. S.M. de la Monte, G.J. Chen, E. Rivera and J.R. Wands, Neuronal thread protein regulation and interaction with microtubule-associated proteins in SH-Sy5y neuronal cells, Cell Mol Life Sci 60(12) (2003), 2679-2691.
22. M. Hong and V.M. Lee, Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons, J Biol Chem 272(31) (1997), 19547-19553.
23. A.D. Bolzan and M.S. Bianchi, Genotoxicity of streptozotocin, Mutat Res 512(2-3) (2002), 121-134.
24. T. Szkudelski, The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas, Physiol Res 50(6) (2001), 537-546.
25. W.R. Markesbery and J.M. Carney, Oxidative alterations in Alzheimer's disease, Brain Pathol 9(1) (1999), 133-146.
26. L.M. Sayre, D.A. Zelasko, P.L. Harris, G. Perry, R.G. Salomon and M.A. Smith, 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease, J Neurochem 68(5) (1997), 2092-2097.
27. S.M. de la Monte, Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer's disease, Ann Neurol 25(5) (1989), 450-459.
28. P. Eikelenboom and W.A. van Gool, Neuroinflammatory perspectives on the two faces of Alzheimer's disease, J Neural Transm 111(3) (2004), 281-294.
29. E.E. Tuppo and H.R. Arias, The role of inflammation in Alzheimer's disease, Int J Biochem Cell Biol 37(2) (2005), 289-305.
30. G.J. Chen, J. Xu, S.A. Lahousse, N.L. Caggiano and S.M. de la Monte, Transient hypoxia causes Alzheimer-type molecular and biochemical abnormalities in cortical neurons: potential strategies for neuroprotection, J Alzheimers Dis 5(3) (2003), 209-228.
31. G.N. Patrick, L. Zukerberg, M. Nikolic, S. de la Monte, P. Dikkes and L.H. Tsai, Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature 402(6762) (1999), 615-622.